2025-10-23 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the data you provided, presented with the requested format and analysis:

**0. Executive Summary**

Merck & Co Inc (MRK) is a global pharmaceutical company. While MRK has positive analyst ratings and recent news indicates expansion and analyst confidence, its recent stock performance has lagged significantly behind the S&P 500 (VOO).  The company's fundamentals show strong profitability, but recent market indicators suggest caution. Short-term caution is required but, overall the analyst consensus for the long term is "Buy".

**1. Performance Relative to S&P 500 (VOO)**

*   **Ticker:** MRK
*   **Company Name:** Merck & Co Inc
*   **Company Overview:** A global pharmaceutical company.
*   **MRK Cumulative Return:** 3.59%
*   **VOO Cumulative Return:** 99.09%
*   **Absolute Deviation:** -96.8%
*   **Relative Deviation:** 5.6%

**Analysis:** MRK has significantly underperformed the S&P 500. The relative deviation suggests MRK's underperformance is near the lower end of its historical range compared to VOO.

**Alpha, Beta Analysis Table:**

| Year       | CAGR  | MDD   | Alpha   | Beta | Cap(B) |
|------------|-------|-------|---------|------|--------|
| 2015-2017  | 1.0%  | 68.5% | -28.0%  | 0.0  | 134.1  |
| 2016-2018  | 36.0% | 69.8% | 21.0%   | -0.0 | 182.1  |
| 2017-2019  | 40.0% | 69.8% | 18.0%   | 0.3  | 216.7  |
| 2018-2020  | 16.0% | 79.6% | -8.0%   | 0.3  | 194.9  |
| 2019-2021  | 2.0%  | 79.6% | -44.0%  | 0.7  | 191.4  |
| 2020-2022  | 15.0% | 79.6% | 16.0%   | 0.7  | 277.1  |
| 2021-2023  | 33.0% | 79.6% | 31.0%   | 0.3  | 272.3  |
| 2022-2024  | -4.0% | 79.6% | -25.0%  | 0.2  | 248.4  |
| 2023-2025  | -46.0%| 71.5% | -109.0% | 1.6  | 218.8  |

*   **CAGR (Compound Annual Growth Rate):**  The CAGR shows a wide range, with significant declines in recent periods (2022-2025).
*   **MDD (Maximum Drawdown):** High MDD values indicate substantial potential losses from peak to trough.
*   **Alpha:** The Alpha values are generally negative, especially in the most recent period.  This indicates MRK has been underperforming relative to its risk-adjusted expected return.
*   **Beta:** Beta values are low, suggesting MRK is less sensitive to market movements than the S&P 500.
*   **Cap (B):** Market capitalization has fluctuated.

**2. Recent Stock Price Movement**

*   **Current Price:** 87.62
*   **Last Market Data:** price: 87.61, previousClose: 87.62, change: -0.01
*   **5-Day Moving Average:** 85.35
*   **20-Day Moving Average:** 85.07
*   **60-Day Moving Average:** 83.47

**Analysis:** The current price is slightly below the previous close with a small change, which is not much. All moving averages are below the current price, indicating a recent upward trend.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 37.72 (Approaching Oversold)
*   **PPO:** -0.0091
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (35 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Delta_Previous_Relative_Divergence:** -3.6 (Short-term Decline)
*   **Expected Return (%):** -121.3% (vs. S&P 500, long term)

**Analysis:**

*   The MRI suggests a high investment recommendation, contradicting the recent underperformance. This could be due to forward-looking factors.
*   The RSI is approaching oversold territory, which *could* signal a potential buying opportunity.
*   The negative PPO suggests a downtrend in price momentum.
*   The hybrid signal recommends buying and investing monthly
*   The Delta_Previous_Relative_Divergence confirms a recent short-term decline.
*   The significantly negative expected return is a major red flag, indicating potential underperformance versus the S&P 500 in the long term.

**4. Recent News & Significant Events**

*   **Valuation Perspective as Groundbreaking Cancer Trial Wins Drive New Investor Focus:** Positive news, suggesting potential future growth.
*   **Jim Cramer Calls Danaher “Once Incredibly Well-Run Company”:** Irrelevant to MRK.
*   **Kenox Pharmaceuticals Appoints Dr. Julianne Berry as Vice President of R&D and Manufacturing:** Irrelevant to MRK.
*   **SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments:** Irrelevant to MRK.
*   **Merck Kicks Off $3 Billion Expansion in Virginia:**  Indicates confidence in future growth and demand.
*   **Analyst Says He’s Buying Merck (MRK) as ‘Market Turns Towards Quality’:** Positive signal, suggesting a shift in market sentiment favoring established companies.

**Analysis:** Recent news is mixed.  The positive news around cancer trials, expansion, and analyst sentiment are encouraging.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.00)
*   **Target Price:** 101.84 (Average) / 137.00 (High) / 82.00 (Low)

**Analysis:** Analysts are generally bullish on MRK, with a consensus "Buy" rating and a significant average target price. However, the low target price is lower than the current price.

**5. Recent Earnings Analysis**

| 날짜         | EPS  | 매출     |
|--------------|------|----------|
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2025-08-05 | 2.15 | 16.11 B$ |

**Analysis:**  Earnings per share (EPS) and revenue have fluctuated.  It's necessary to look at a longer period to determine a trend. There appears to be a typo (2025-08-05 appearing twice).

**6. Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30 | $15.81B   | 77.50%       |
| 2025-03-31 | $15.53B   | 77.98%       |
| 2024-12-31 | $15.62B   | 75.50%       |
| 2024-09-30 | $16.66B   | 75.51%       |
| 2024-06-30 | $16.11B   | 76.76%       |

Capital and Profitability:

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-06-30 | $48.99B   | 9.04%   |
| 2025-03-31 | $48.34B   | 10.51%  |
| 2024-12-31 | $46.31B   | 8.08%   |
| 2024-09-30 | $44.50B   | 7.09%   |
| 2024-06-30 | $43.58B   | 12.52%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been relatively stable over the last five quarters, with strong profit margins consistently above 75%.
*   **Capital and Profitability:** Equity has been steadily increasing. Return on Equity (ROE) has fluctuated, indicating varying levels of efficiency in using equity to generate profits.

**7. 종합적 분석 (Overall Analysis)**

MRK presents a mixed picture:

*   **Negative Factors:**
    *   Significant underperformance relative to the S&P 500.
    *   Negative expected return compared to the S&P 500.
    *   High Maximum Drawdown.
    *   Negative Alpha values.
*   **Positive Factors:**
    *   Strong profitability and healthy profit margins.
    *   Positive analyst consensus ("Buy").
    *   Recent positive news regarding cancer trials and expansion.
    *   High Market Risk Indicator (MRI).
    *   Rising Equity

**Conclusion:**

The recent performance of MRK warrants caution. While the analyst consensus is positive and the company exhibits strong fundamentals, the underperformance relative to the S&P 500 and the negative expected return are concerning. However, the relatively high MRI indicates that the market views MRK as a good investment target. Considering the negative short term divergence in stock performance, current market environment suggests investors should be cautious.

**Recommendation:** Due diligence is warranted before investing in MRK, and investors should consider the potential risks. It's important to monitor future earnings reports, market sentiment, and news events. Given the significant expected return vs. S&P 500, the overall analyst consensus for the long term is "Buy", and investors may want to take an appropriate position.
